638 related articles for article (PubMed ID: 26466871)
1. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
[TBL] [Abstract][Full Text] [Related]
2. Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
Neubauer DN
Drugs Today (Barc); 2015 Jan; 51(1):29-35. PubMed ID: 25685859
[TBL] [Abstract][Full Text] [Related]
3. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
Johnsa JD; Neville MW
Ann Pharmacother; 2014 Dec; 48(12):1636-41. PubMed ID: 25204464
[TBL] [Abstract][Full Text] [Related]
4. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.
Keating GM
CNS Drugs; 2016 May; 30(5):461-8. PubMed ID: 27003694
[TBL] [Abstract][Full Text] [Related]
5. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
Rajaratnam SM; Polymeropoulos MH; Fisher DM; Roth T; Scott C; Birznieks G; Klerman EB
Lancet; 2009 Feb; 373(9662):482-91. PubMed ID: 19054552
[TBL] [Abstract][Full Text] [Related]
6. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
Nishimon S; Nishimon M; Nishino S
Expert Opin Pharmacother; 2019 Jun; 20(9):1065-1073. PubMed ID: 30990759
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.
Stahl SM
CNS Spectr; 2014 Dec; 19(6):475-8. PubMed ID: 25422900
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind.
Emens JS; Eastman CI
Drugs; 2017 Apr; 77(6):637-650. PubMed ID: 28229310
[TBL] [Abstract][Full Text] [Related]
9. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
Bonacci JM; Venci JV; Gandhi MA
J Pharm Pract; 2015 Oct; 28(5):473-8. PubMed ID: 25092604
[TBL] [Abstract][Full Text] [Related]
10. Caffeine does not entrain the circadian clock but improves daytime alertness in blind patients with non-24-hour rhythms.
St Hilaire MA; Lockley SW
Sleep Med; 2015 Jun; 16(6):800-4. PubMed ID: 25891543
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
Leger D; Quera-Salva MA; Vecchierini MF; Ogrizek P; Perry CA; Dressman MA
Expert Opin Drug Saf; 2015; 14(11):1673-85. PubMed ID: 26393492
[TBL] [Abstract][Full Text] [Related]
12. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.
Hardeland R
Curr Opin Investig Drugs; 2009 Jul; 10(7):691-701. PubMed ID: 19579175
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
14. Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder.
Med Lett Drugs Ther; 2014 Apr; 56(1441):34-5. PubMed ID: 24759294
[No Abstract] [Full Text] [Related]
15. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
17. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
18. Entrainment of free-running circadian rhythms by melatonin in blind people.
Sack RL; Brandes RW; Kendall AR; Lewy AJ
N Engl J Med; 2000 Oct; 343(15):1070-7. PubMed ID: 11027741
[TBL] [Abstract][Full Text] [Related]
19. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
Dodick DW; Goadsby PJ; Spierings EL; Scherer JC; Sweeney SP; Grayzel DS
Lancet Neurol; 2014 Sep; 13(9):885-92. PubMed ID: 25127173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]